Literature DB >> 23229585

Antibody crossreactivity between the tumour suppressor PHLPP1 and the proto-oncogene β-catenin.

Viola H Lobert, Jarle Bruun, Hilde Abrahamsen, Ragnhild A Lothe, Harald Stenmark, Matthias Kolberg, Coen Campsteijn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23229585      PMCID： PMC3537141          DOI： 10.1038/embor.2012.188

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  4 in total

1.  Scribble-mediated membrane targeting of PHLPP1 is required for its negative regulation of Akt.

Authors:  Xin Li; Haihua Yang; Jianyu Liu; Micheal D Schmidt; Tianyan Gao
Journal:  EMBO Rep       Date:  2011-06-24       Impact factor: 8.807

2.  Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome.

Authors:  Solveig Sirnes; Jarle Bruun; Matthias Kolberg; Ane Kjenseth; Guro E Lind; Aud Svindland; Andreas Brech; Arild Nesbakken; Ragnhild A Lothe; Edward Leithe; Edgar Rivedal
Journal:  Int J Cancer       Date:  2011-10-20       Impact factor: 7.396

3.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Authors:  David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu
Journal:  Cancer Cell       Date:  2011-05-27       Impact factor: 31.743

4.  Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis.

Authors:  J Liu; H L Weiss; P Rychahou; L N Jackson; B M Evers; T Gao
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867
  4 in total
  5 in total

1.  Pharmacological inhibition of pleckstrin homology domain leucine-rich repeat protein phosphatase is neuroprotective: differential effects on astrocytes.

Authors:  Travis C Jackson; Jonathan D Verrier; Tomas Drabek; Keri Janesko-Feldman; Delbert G Gillespie; Thomas Uray; Cameron Dezfulian; Robert S Clark; Hülya Bayir; Edwin K Jackson; Patrick M Kochanek
Journal:  J Pharmacol Exp Ther       Date:  2013-09-10       Impact factor: 4.030

2.  Response: 'Antibody crossreactivity between the tumour suppressor PHLPP1 and the proto-oncogene β-catenin'.

Authors:  Eric W McIntush
Journal:  EMBO Rep       Date:  2013-05-17       Impact factor: 8.807

3.  Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.

Authors:  Hale Samli; Murat Samli; Buse Vatansever; Sena Ardicli; Nazlihan Aztopal; Deniz Dincel; Ahmet Sahin; Faruk Balci
Journal:  World J Urol       Date:  2018-09-22       Impact factor: 4.226

4.  Detection of PHLPP1α/β in human and mouse brain by different anti-PHLPP1 antibodies.

Authors:  Travis C Jackson; Hülya Bayir; Milos D Ikonomovic; Keri Janesko-Feldman; Zaichuan Mi; Tianyan Gao; Edwin K Jackson; Patrick M Kochanek
Journal:  Sci Rep       Date:  2015-04-01       Impact factor: 4.379

5.  When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions.

Authors:  Andrew R M Bradbury; Nathan D Trinklein; Holger Thie; Ian C Wilkinson; Atul K Tandon; Stephen Anderson; Catherine L Bladen; Brittany Jones; Shelley Force Aldred; Marco Bestagno; Oscar Burrone; Jennifer Maynard; Fortunato Ferrara; James S Trimmer; Janina Görnemann; Jacob Glanville; Philipp Wolf; Andre Frenzel; Julin Wong; Xin Yu Koh; Hui-Yan Eng; David Lane; Marie-Paule Lefranc; Mike Clark; Stefan Dübel
Journal:  MAbs       Date:  2018-03-29       Impact factor: 5.857
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.